<br>        Inclusion Criteria:<br><br>          -  Signed written informed consent;<br><br>          -  Males or females between 18 and 70 years of age;<br><br>          -  Surgically resected squamous cell carcinomas of the hypopharynx, oropharynx, larynx<br>             and oral cavity with high risk of locoregional recurrence not more than 6-9 weeks<br>             (maximum) ago;<br><br>          -  To be categorized as high risk patients have to fulfil at least one of the following<br>             criteria:<br><br>               -  R0 - resection <5 mm margin<br><br>               -  R1 - resection<br><br>               -  Extracapsular nodal extension;<br><br>          -  no previous chemotherapy, radiotherapy;<br><br>          -  Performance status ECOG: 0 - 1;<br><br>          -  Contraception in male and female patients if of childbearing potential, willingness<br>             to use effective contraceptive method for the study duration and 2 months<br>             post-dosing;<br><br>          -  Adequate renal, liver and hematological functions (within maximum 9 weeks until<br>             surgery):<br><br>               -  Adequate bone marrow function: neutrophils > 1.5 x 10^9/L, platelets > 100 x<br>                  10^9/L, hemoglobin > 10.0 g/dL<br><br>               -  Adequate liver function: Bilirubin < 2.0 mg/dL, AST, ALT, AP, ?-GT < 3 x ULN<br><br>               -  Adequate renal function: creatinine clearance > =60 ml/min<br><br>          -  No distant metastases;<br><br>        Exclusion Criteria:<br><br>          -  Nasopharyngeal carcinoma;<br><br>          -  R2 resection;<br><br>          -  Invalid informed consent;<br><br>          -  Performance Status > 1;<br><br>          -  Previous chemotherapy or radiotherapy for carcinoma of the head and neck;<br><br>          -  Prior exposure to EGFR pathway targeting therapy;<br><br>          -  Other serious illness or medical conditions:<br><br>               -  Unstable cardiac disease despite treatment, congestive heart failure NYHA grade<br>                  3 and 4;<br><br>               -  Clinically significantly abnormal electrocardiogram (ECG) or left ventricular<br>                  ejection fraction (LVEF) below the institutional range of the normal<br><br>               -  Significant neurologic or psychiatric disorders including dementia or seizures;<br><br>               -  Active uncontrolled infection;<br><br>               -  Active disseminated intravascular coagulation;<br><br>               -  Other serious underlying medical conditions which could impair the ability of<br>                  the patient to participate in the study;<br><br>          -  Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria<br>             (NCI-CTC v3.0) grade 2 or ototoxicity grade 2, except if due to trauma or mechanical<br>             impairment due to tumor mass;<br><br>          -  Having participated in another therapeutic clinical trial or any investigational<br>             agent in the preceding 30 days;<br><br>          -  Known allergic/hypersensitivity reaction to any of the components of the treatment;<br><br>          -  Pregnancy (absence confirmed by serum/urine ß-HCG) or breast-feeding;<br><br>          -  Known drug abuse;<br><br>          -  Other previous malignancy within 5 years, with exception of a history of a previous<br>             basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix;<br><br>          -  Legal incapacity or limited legal capacity;<br><br>          -  Sensitivity and incompatibility against 5-Fluorouracil<br><br>          -  Sensitivity and incompatibility against platinum-compounds<br><br>          -  Known incompatibilities >grade 3 towards cetuximab<br><br>          -  expected incompliance of patient (e.g. in case of severe alcohol addiction)<br><br>          -  Dental evaluation: Pre treatment dental care before start of radiochemotherapy<br>             (approximately 8 to 10 days lapse-time is needed for complete recovery before<br>             initiation of radiation therapy).<br>